Press "Enter" to skip to content

“The first dose of German vaccine protection rate is 80 percent” – Health News


Hacettepe University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Professor. Dr. Murat Akova, originating in China corona virus vaccine Phase 3 study in Turkey has said it terminated with 10 thousand 250 volunteers.

Noting that the analysis of this study has been done now, Akova said, “We are evaluating the data we have in order to explain new results on the intermediate results. We aim to evaluate the data we have as much as possible and reach a conclusion. “We could follow up for a long time. At this stage, the evaluation of those data continues,” he said.

“THEY WILL BE FOLLOWED FOR 1 YEAR TIME”

Akova emphasized that there is no Phase-3 study that has been concluded at the moment and said, “For the conclusion of all these studies, all of their hearts will be followed up for 2 years in the Pfizer / BioNTech study, and for 1 year in our study. All of these are an interim analysis, so there are 44,000 volunteers in the German vaccine, 30,000 in the Moderna vaccine, nearly 30,000 in the Oxford / AstraZeneca vaccine, and the Russian vaccine will include around 20,000 volunteers. “The efficiency of the Oxford / AstraZeneca and Moderna vaccine is around 95 percent, and the efficiency of the vaccine produced by the Russians is around 91 percent.”

“80 PERCENT ACTIVITIES IN A SINGLE DOSE”

Akova noted that the Pfizer / BioNTech vaccine had around 44 thousand volunteers, all evaluations were made on this number, and that 94.5 percent efficiency was achieved with that assessment.

Akova, “The German vaccine seems to be 94.5 percent as a result of effectiveness. There is a new data about the German vaccine. It is estimated that this vaccine is quite protective after the first dose. Data from Israel point out this. Those who have taken a single dose of German vaccine.” “There are data indicating that there is more than 80 percent of activity. Of course, the longer the monitoring periods of these volunteers, the more different types of data can be obtained,” he said.

Akova also said about the domestic vaccine, “Looking at the experiences from the past, I think that if everything goes well, such a vaccine can be quickly completed and released to the market in the second half of 2021. It is not possible to wait for anything before that.”

Download the NTV application, stay up to date

THEY DIDN’T GO TO THE ELDERLY TO BE THE CORONA VIRUS VACCINE


Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *